Compare Cytokinetics Inc (CYTK) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs PepsiCo, Inc. — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while PepsiCo, Inc. trades at $135.8 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 16.6× Cytokinetics Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PEP | |
|---|---|---|
Market Cap | $11.12B | $184.87B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $170.44 |
52-Week Low | $33.23 | $133.81 |
Enterprise Value | $11.59B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
PepsiCo (PEP) trades at $138.49, up 0.81% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly EPS beats and maintains robust profitability with 10.78% net margin and 51.59% ROE. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts maintain a consensus price target of $159.27 with 33% buy ratings.
PEP offers stable dividend income and consistent earnings growth potential, though near-term technical weakness and pricing strategy adjustments present headwinds. The stock trades at reasonable valuation multiples (P/E 17.75) with upside to analyst targets, but investors should monitor North American performance recovery and consumer pricing sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
